Biosimilars Market Access in Psoriasis 2017 - Physicians Hesitant to Use Biosimilars, But Understand that Payers May Hold Sway - Research and Markets

DUBLIN, May 18, 2017 /PRNewswire/ --

Dublin - Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

• Insights and strategic recommendations
• Inflectra carries biosimilar labeling designation, but is not interchangeable
• Physicians hesitant to use biosimilars, but understand that payers may hold sway
• Bibliography
  

2. Five Major EU Markets

• Insights and strategic recommendations
• Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
• Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
• Payers use biosimilars to pressure originators on pricing
• Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
• Biosimilars will be used as price benchmarks for pipeline agents
• Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
• Bibliography
  

3. Methodology

• Primary research
  

For more information about this report visit http://www.researchandmarkets.com/research/dr3pv9/biosimilars

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilars-market-access-in-psoriasis-2017---physicians-hesitant-to-use-biosimilars-but-understand-that-payers-may-hold-sway---research-and-markets-300460233.html

SOURCE Research and Markets